Skip to main content
NCBI home page
Nucleic Acids Research logoLink to Nucleic Acids Research
. 1997 Sep 1;25(17):3451–3458. doi: 10.1093/nar/25.17.3451

Cleavage of collagen RNA transcripts by hammerhead ribozymes in vitro is mutation-specific and shows competitive binding effects.

G Grassi 1, A Forlino 1, J C Marini 1
PMCID: PMC146924  PMID: 9254703

Abstract

We report here the in vitro use of hammerhead ribozymes as an approach to the gene therapy of osteogenesis imperfecta (OI). Our strategy for the treatment of this dominant genetic disorder is based on selective reduction of the level of the mRNA transcripts from the mutant allele. We studied the in vitro cleavage activity of five different hammerhead ribozymes targeted against synthetic transcripts of two naturally occurring human collagen mutations and against a point mutation introduced into a construct containing a portion of the mouse COL1A1 gene. This is the first demonstration that ribozyme cleavage is absolutely dependent on the presence of the ribozyme cleavage site introduced by the disease-causing mutation. Cleavage specificity and activity were unchanged when the cleavage site was located in transcripts of progressively longer length. Cleavage efficiency depended directly on the ratio of ribozyme/substrate, as well as on the time and temperature of incubation. We investigated the competitive effects of both total RNA and normal synthetic transcripts on ribozyme cleavage activity. The ribozyme was able to localize and cleave its specific target even in the presence of a vast excess of total RNA. However, cleavage efficiency was linearly inhibited by the presence of a non- cleavable competitor substrate which contained a ribozyme binding site identical to the site present in the cleavable target. Although this competition could be eliminated by introducing a mismatch into one ribozyme binding arm, the presence of the mismatch decreased ribozyme cleavage efficiency. The mutation- specificity of ribozyme cleavage demonstrated in this work provides support for in vivo studies aimed at ribozyme development as a treatment for dominant negative genetic disorders.

Full Text

The Full Text of this article is available as a PDF (288.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bertrand E. L., Rossi J. J. Facilitation of hammerhead ribozyme catalysis by the nucleocapsid protein of HIV-1 and the heterogeneous nuclear ribonucleoprotein A1. EMBO J. 1994 Jun 15;13(12):2904–2912. doi: 10.1002/j.1460-2075.1994.tb06585.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bruening G. Compilation of self-cleaving sequences from plant virus satellite RNAs and other sources. Methods Enzymol. 1989;180:546–558. doi: 10.1016/0076-6879(89)80123-5. [DOI] [PubMed] [Google Scholar]
  3. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  4. Forster A. C., Symons R. H. Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites. Cell. 1987 Apr 24;49(2):211–220. doi: 10.1016/0092-8674(87)90562-9. [DOI] [PubMed] [Google Scholar]
  5. Grassi G., Marini J. C. Ribozymes: structure, function, and potential therapy for dominant genetic disorders. Ann Med. 1996 Dec;28(6):499–510. doi: 10.3109/07853899608999114. [DOI] [PubMed] [Google Scholar]
  6. Haseloff J., Gerlach W. L. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature. 1988 Aug 18;334(6183):585–591. doi: 10.1038/334585a0. [DOI] [PubMed] [Google Scholar]
  7. Hertel K. J., Herschlag D., Uhlenbeck O. C. Specificity of hammerhead ribozyme cleavage. EMBO J. 1996 Jul 15;15(14):3751–3757. [PMC free article] [PubMed] [Google Scholar]
  8. Inouye M. Antisense RNA: its functions and applications in gene regulation--a review. Gene. 1988 Dec 10;72(1-2):25–34. doi: 10.1016/0378-1119(88)90124-2. [DOI] [PubMed] [Google Scholar]
  9. Kilpatrick M. W., Phylactou L. A., Godfrey M., Wu C. H., Wu G. Y., Tsipouras P. Delivery of a hammerhead ribozyme specifically down-regulates the production of fibrillin-1 by cultured dermal fibroblasts. Hum Mol Genet. 1996 Dec;5(12):1939–1944. doi: 10.1093/hmg/5.12.1939. [DOI] [PubMed] [Google Scholar]
  10. Kohn D. B., Anderson W. F., Blaese R. M. Gene therapy for genetic diseases. Cancer Invest. 1989;7(2):179–192. doi: 10.3109/07357908909038283. [DOI] [PubMed] [Google Scholar]
  11. Marini J. C. Osteogenesis imperfecta: comprehensive management. Adv Pediatr. 1988;35:391–426. [PubMed] [Google Scholar]
  12. Melton D. A. Injected anti-sense RNAs specifically block messenger RNA translation in vivo. Proc Natl Acad Sci U S A. 1985 Jan;82(1):144–148. doi: 10.1073/pnas.82.1.144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Papaphilis A. D., Kamper E. F., Grammenou S., Kattamis C., Pangalis G. A. RNase H of human leukemic cells: a new biological parameter in the study of human leukemias (review). Anticancer Res. 1990 Sep-Oct;10(5A):1201–1212. [PubMed] [Google Scholar]
  14. Perriman R., Delves A., Gerlach W. L. Extended target-site specificity for a hammerhead ribozyme. Gene. 1992 Apr 15;113(2):157–163. doi: 10.1016/0378-1119(92)90391-2. [DOI] [PubMed] [Google Scholar]
  15. Rossi J. J. Controlled, targeted, intracellular expression of ribozymes: progress and problems. Trends Biotechnol. 1995 Aug;13(8):301–306. doi: 10.1016/S0167-7799(00)88969-6. [DOI] [PubMed] [Google Scholar]
  16. Ruffner D. E., Stormo G. D., Uhlenbeck O. C. Sequence requirements of the hammerhead RNA self-cleavage reaction. Biochemistry. 1990 Nov 27;29(47):10695–10702. doi: 10.1021/bi00499a018. [DOI] [PubMed] [Google Scholar]
  17. Sun L. Q., Pyati J., Smythe J., Wang L., Macpherson J., Gerlach W., Symonds G. Resistance to human immunodeficiency virus type 1 infection conferred by transduction of human peripheral blood lymphocytes with ribozyme, antisense, or polymeric trans-activation response element constructs. Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7272–7276. doi: 10.1073/pnas.92.16.7272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Symons R. H. Small catalytic RNAs. Annu Rev Biochem. 1992;61:641–671. doi: 10.1146/annurev.bi.61.070192.003233. [DOI] [PubMed] [Google Scholar]
  19. Tsuchihashi Z., Khosla M., Herschlag D. Protein enhancement of hammerhead ribozyme catalysis. Science. 1993 Oct 1;262(5130):99–102. doi: 10.1126/science.7692597. [DOI] [PubMed] [Google Scholar]
  20. Uhlenbeck O. C. A small catalytic oligoribonucleotide. Nature. 1987 Aug 13;328(6131):596–600. doi: 10.1038/328596a0. [DOI] [PubMed] [Google Scholar]
  21. Wang Q., Forlino A., Marini J. C. Alternative splicing in COL1A1 mRNA leads to a partial null allele and two In-frame forms with structural defects in non-lethal osteogenesis imperfecta. J Biol Chem. 1996 Nov 8;271(45):28617–28623. doi: 10.1074/jbc.271.45.28617. [DOI] [PubMed] [Google Scholar]
  22. Wang Q., Marini J. C. Antisense oligodeoxynucleotides selectively suppress expression of the mutant alpha 2(I) collagen allele in type IV osteogenesis imperfecta fibroblasts. A molecular approach to therapeutics of dominant negative disorders. J Clin Invest. 1996 Jan 15;97(2):448–454. doi: 10.1172/JCI118434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Wang Q., Orrison B. M., Marini J. C. Two additional cases of osteogenesis imperfecta with substitutions for glycine in the alpha 2(I) collagen chain. A regional model relating mutation location with phenotype. J Biol Chem. 1993 Nov 25;268(33):25162–25167. [PubMed] [Google Scholar]
  24. Werner M., Uhlenbeck O. C. The effect of base mismatches in the substrate recognition helices of hammerhead ribozymes on binding and catalysis. Nucleic Acids Res. 1995 Jun 25;23(12):2092–2096. doi: 10.1093/nar/23.12.2092. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Willing M. C., Deschenes S. P., Slayton R. L., Roberts E. J. Premature chain termination is a unifying mechanism for COL1A1 null alleles in osteogenesis imperfecta type I cell strains. Am J Hum Genet. 1996 Oct;59(4):799–809. [PMC free article] [PubMed] [Google Scholar]
  26. Zhou C., Bahner I. C., Larson G. P., Zaia J. A., Rossi J. J., Kohn E. B. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Gene. 1994 Nov 4;149(1):33–39. doi: 10.1016/0378-1119(94)90409-x. [DOI] [PubMed] [Google Scholar]
  27. Zoumadakis M., Tabler M. Comparative analysis of cleavage rates after systematic permutation of the NUX consensus target motif for hammerhead ribozymes. Nucleic Acids Res. 1995 Apr 11;23(7):1192–1196. doi: 10.1093/nar/23.7.1192. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Nucleic Acids Research are provided here courtesy of Oxford University Press

RESOURCES